Cyclised conotoxin peptides

Details Cyclised conotoxin peptides Cyclised conotoxin peptides

2007-12-25

2007-12-25

Kam, Chih-Min (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C514S013800, C514S021800, C530S317000, C530S324000, C530S326000, C530S334000, C530S344000, C424S009100

Reexamination Certificate

active

11052168

ABSTRACT:
This invention relates to cyclised conotoxin peptides, processes for their preparation and their pharmaceutical use.

REFERENCES:
patent: 4447356 (1984-05-01), Olivera et al.
patent: 5589356 (1996-12-01), Tam
patent: 7001883 (2006-02-01), Craik et al.
patent: WO 96/33206 (1996-10-01), None
patent: WO-96/33206 (1996-10-01), None
patent: WO 96/34878 (1996-11-01), None
patent: WO 98/03541 (1998-01-01), None
patent: WO 98/20026 (1998-05-01), None
patent: WO 98/28434 (1998-07-01), None
patent: WO 98/56807 (1998-12-01), None
Armishaw et al. , American Peptide Society, pp. 113-114, 2001.
Al-Obeidi, F., et al., “Potent and prolonged acting cyclic lactam analogues of α-melanotropin: design based on molecular dynamics,”J. Med. Chem., 1989, 32, 2555-2561.
Armishaw, C.J., et al., “Synthesis of backbone cyclic analogues of α-conotoxin IMI by chemoselective ligation of unprotected linear precursors,” Benedetti, E., et al. (Eds.),Peptides, 2002, 1 page (Abstract).
Armishaw C.J., et al., “Synthesis of N to C terminal cyclic analogues of α-conotoxin ImI by chemoselective ligation of unprotected linear precursors,”Peptides: The Wave of the Future, Lebl, M., et al. (Eds.),American Peptide Society, 2001, 113-114.
Botti, P., et al., “Cyclic peptides from linear unprotected peptide precursors through thiazolidine formation,”J. Am. Chem. Soc., 1996, 118, 10018-10024.
Byk, G., et al., “Synthesis and biological activity of NK-1 selective, N-backbone cyclic analogs of the C-terminal hexapeptide of substance P,”J. Med. Chem., 1996, 39, 3174-3178.
Charpentier, B., et al., “Synthesis and binding affinities of cyclic and related linear analogues of CCK8selective for central receptors,”J. Med. Chem., 1989, 32, 1184-1190.
Chazin, W.J., et al., “Comparative studies of conformation and internal mobility in native and circular basic pancreatic trypsin inhibitor by1H nuclear magnetic resonance in solution,”Eur. J. Biochem., 1985, 152, 429-437.
Chu, V., et al., “Thermodynamic and structural consequences of flexible loop deletion by circular permutation in the streptavidin-biotin system,”Protein Science, 1998, 7, 848-859.
Claeson, P., et al., “Fractionation protocol for the isolation of polypeptides from plant biomass,”J. Nat. Prod., 1998, 61, 77-81.
Feng, Y., et al., “Circular permutation of granulocyte colony-stimulating factor,”Biochemistry, 1999, 38, 4553-4563.
Garrett, J.B., et al., “Are turns required for the folding of ribonuclease T1?,”Protein Science, 1996, 5, 204-211.
Gilon, C., et al., “Backbone cyclization: a new method for conferring conformational constraint on peptides,”Biopolymers, 1991, 31, 745-750.
Goldenberg, D.P., et al., “Circular and circularly permuted forms of bovine pancreatic trypsin inhibitor,”J. Mol. Biol., 1983, 165, 407-413.
Goldenberg, D.P., et al., “Folding pathway of a circular form of bovine pancreatic trysin inhibitor,”J. Mol. Biol., 1984, 179, 527-545.
Goldenberg, D.P., “Dissecting the roles of individual interactions in protein stability: lessons from a circularized protein,”J. Cellular Biochemistry, 1985, 29, 321-335.
Gray, W.R., et al., “Conotoxin MI—Disulfide bonding and conformational states,”J. Biological Chemistry, Oct. 25, 1983, 258(20), 12247-12251.
Gutknecht, R., et al., “The glucose transporter ofEscherichia coliwith circularly permuted domains is active in vivo and in vitro,”J. Biological Chemistry, Oct. 2, 1998, 273(40), 25745-25750.
Hennecke, J., et al., “Conversion of a catalytic into a structural disulfide bond by circular permutation,”Biochemistry, 1998, 37, 17590-17597.
Hruby, V.J., “Design of peptide hormone and neurotransmitter analogues,”TIPS, Jun. 1985, 259-262.
Hruby, V.J., “Conformational restrictions of biologically active peptides via amino acid side chain groups,”Life Sciences, 1982, 31(3), 189-199.
Jackson, D.Y., et al., “Enzymatic cyclization of linear peptide esters using subtiligase,”J. Am. Chem. Soc., 1995, 117, 819-820.
Jacobsen, R.B., et al., “A novel D-leucine-containingconuspeptide: diverse conformational dynamics in the contryphan family,”J. Peptide Res., 1999, 54, 93-99.
Kreitman, R.J., “A circularly permuted recombinant interleukin 4 toxin with increased activity,”Proc. Natl. Acad. Sci. USA, Jul. 1994, 91, 6889-6893.
Kreitman, R.J., et al., “Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma,”Cancer Research, Aug. 1, 1995, 3357-3363.
Lender, A., et al., “Design and synthesis of sulfur-free cyclic hexapeptides which contain the RGD sequence and bind to the fibrinogen GP IIb/IIIa,”Int. J. Peptide Protein Res., 1993, 42, 509-517.
Muir, T.W., et al., “Expressed protein ligation: a general method for protein engineering,”Proc. Natl. Acad. Sci. USA, Jun. 1998, 95, 6705-6710.
Myers, R.A., et al., “Conuspeptides as chemical probes for receptors and ion channels,”Chem. Rev., 1993, 93, 1923-1936.
Okumu, F.W., et al., “Effect of restricted conformational flexibility on the permeation of model hexapeptides across caco-2 cell monolayers,”Pharmaceutical Res., 1997, 14(2), 169-175.
Olivera, B.M., et al., “Minireview: Conotoxins,”J. Biological Chemistry, Nov. 25, 1991, 266(33), 22067-22070.
Olivera, B.M., “Diversity ofConusneuropeptides,”Science, Jul. 20, 1990, 249, 257-250.
Pallaghy, P.K., et al., “A common structural motif incorporating a cystine knot and a triple-stranded β-sheet in toxic and inhibitory polypeptides,”Protein Science, 1994, 3, 1833-1839.
Rivier, J.E., et al., “Bicyclic gonadotropin releasing bormone (GnRH) antagonists,”Peptides Chemistry, Structure and Biology, 1990, 33-37.
Rote, K.V., et al., “Circular pancreatic trypsin inhibitor: A novel substrate for studies on intracellular proteolysis,”J. Biological Chemistry, Jan. 15, 1989, 264(2), 1156-1162.
Saether, O., et al., “Elucidation of the primary and three-dimensional structure of the uterotonic polypeptide kalata B1,”Biochemistry, 1995, 34, 4147-4158.
Tam, J.P., et al., “Thia zip reaction for synthesis of large cyclic peptides: mechanisms and applications,”J. Am. Chem. Soc., 1999, 121, 4316-4324.
Tam, J.P., et al., “Synthesis of large cyclic cystine-knot peptide by orthogonal coupling strategy using unprotected peptide precursor,”Tetrahedron Letters, 1997, 38(32), 5599-5602.
Tam, J.P., “A biomimetic strategy in the synthesis and fragmentation of cyclic protein,”Protein Science, 1998, 7, 1583-1592.
Terada, S., et al., “Synthesis and hydrolysis by pepsin and trypsin of a cyclic hexapeptide containing lysine and phenylalanine,”Eur. J. Biochem., 1975, 52, 273-282.
Wieligmann, K., et al., “Eye lens βB2-crystallin: circular permutation does not influence the oligomerization state but enhances the conformational stability,”J. Mol. Biol., 1998, 280, 721-729.
Zhang, L., et al., “Synthesis and application of unprotected cyclic peptides as building blocks for peptide dendrimers,”J. Am. Chem. Soc., 1997, 119, 2363-2370.

Affiliated with

Also associated with

Rating

Cyclised conotoxin peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclised conotoxin peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclised conotoxin peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3845656